Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. Our clinical-stage product candidates include: Phase 3 HEPLISAV-B ™ Adult Hepatitis B Vaccine Phase 1/2 Cancer Immunotherapy Phase 2 Asthma Therapy - Partnered with AstraZeneca In Europe, Dynavax manufactures Hepatitis B surface antigen for HEPLISAV-B.

Type
Public
HQ
Berkeley, US
Size (employees)
251 (est)+8%
Dynavax Technologies is headquartered in Berkeley, US

Dynavax Technologies Office Locations

Dynavax Technologies has an office in Berkeley
Berkeley, US (HQ)
100 2929 Seventh Street

Dynavax Technologies Data and Metrics

Dynavax Technologies Financial Metrics

Dynavax Technologies's revenue was reported to be $11 m in FY, 2016 which is a 173% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

11 m

Revenue growth (FY, 2015 - FY, 2016), %

173%

Net income (FY, 2016)

(112.4 m)

EBIT (FY, 2016)

(110.7 m)

Market capitalization (28-Apr-2017)

246.2 m

Closing share price (28-Apr-2017)

5.7

Cash (31-Dec-2016)

24.3 m
Dynavax Technologies's current market capitalization is $246.2 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.3 m11 m4.1 m11 m

Revenue growth, %

(2%)(63%)173%

R&D expense

50.9 m84.6 m86.9 m84.5 m

General and administrative expense

25.9 m17.4 m22.2 m37.3 m

Operating expense total

77.7 m102.3 m109.1 m121.8 m

EBIT

(66.5 m)(91.3 m)(105.1 m)(110.7 m)

EBIT margin, %

(591%)(828%)(2594%)(1003%)

Interest expense

(35 k)(572 k)(572 k)

Interest income

116 k191 k205 k755 k

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

23.1 m49.5 m44.8 m24.3 m

Accounts Receivable

1.6 m727 k1.4 m

Inventories

1.4 m4.1 m2.4 m6.8 m

Current Assets

192.4 m127.4 m199.9 m89.6 m

PP&E

8.7 m7.9 m13.8 m17.2 m

Goodwill

2.6 m2.3 m2 m2 m

Total Assets

204.6 m138.3 m216.6 m109.7 m

Accounts Payable

1.9 m1.2 m3.4 m3.8 m

Total Debt

9.6 m

Current Liabilities

16.2 m20.3 m28.8 m20 m

Non-Current Liabilities

2.1 m17.5 m769 k443 k

Total Liabilities

18.3 m37.8 m29.6 m20.5 m

Additional Paid-in Capital

688.4 m695.1 m889.7 m905 m

Retained Earnings

(502.2 m)(592.9 m)(699.7 m)(812.2 m)

Total Equity

186.3 m100.5 m187.1 m89.2 m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.4 x1.2 x1.2 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)

Depreciation and Amortization

1.3 m1.4 m1.4 m2.3 m

Accounts Receivable

(622 k)900 k(667 k)52 k

Inventories

677 k(2.7 m)1.6 m560 k

Accounts Payable

(657 k)(523 k)1.2 m1.2 m

Cash From Operating Activities

(58.7 m)(73.7 m)(92.6 m)(107.1 m)

Cash From Investing Activities

(51.4 m)90.6 m(85.8 m)86.2 m

Cash From Financing Activities

125.4 m9.9 m174 m531 k

Interest Paid

720 k
Numbers are in $, USDY, 2016

Revenue/Employee

47.2 k

Financial Leverage

1.2 x

Dynavax Technologies Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

3

Phase I Trials

2

Phase Preclinical

2

Patents (US)

30

Patents (foreign)

260

Patents Pending

40

Dynavax Technologies Market Value History

Dynavax Technologies Revenue Breakdown

Dynavax Technologies Company Life and Culture

You may also be interested in